Protective effect of soybean saponins and major antioxidants against aflatoxin B1-induced mutagenicity and DNA-adduct formation.
Saponins from various plant sources have been suggested as possible anticarcinogens. Major dietary sources of saponins include legumes such as soybeans. This study was performed to determine the effect of soybean saponins on aflatoxin B(1)(AFB(1))-induced mutagenicity and AFB(1)-DNA adduct formation using Salmonella typhimurium and human liver hepatoma (HepG2) cells, respectively. Major antioxidants including L-ascorbic acid, alpha-tocopherol, all-trans-retinol, and butylated hydroxytoluene (BHT), previously reported to possess antimutagenic activity, were used as test materials to evaluate the relative effectiveness of saponins. Results indicated antimutagenicity was in the order of BHT > saponins > alpha-tocopherol > L-ascorbic acid. Soybean saponins exerted a significant effect, inhibiting the mutagenicity of AFB(1) by 52%, 64%, and 81% at concentrations of 600, 900, and 1,200 microg per plate, respectively. The amount of tritiated AFB(1) metabolites-DNA adducts formed in HepG2 cells was significantly reduced when cells were preincubated with 10 or 30 microg/ml of test materials. Soybean saponins inhibited AFB(1)-DNA adduct formation by 50.1% at a concentration of 30 microg/ml, whereas L-ascorbic acid and BHT reduced adduct formation by 38.4% and 32.6%, respectively, at the same concentrations. These results indicate that soybean saponins possess not only a significant antimutagenic activity but a strong inhibitory action against carcinogen-induced DNA damages. Soybean saponins possibly block the initiation stage of carcinogenesis, and further studies are required to elucidate the mechanisms of action.
Jun
Hye-Seung
HS
Department of Food and Nutrition, Sookmyung Womens' University, Seoul, Korea.
Kim
Sung-Eun
SE
Sung
Mi-Kyung
MK
D016604:Aflatoxin B1 / Q000633:toxicity; D016588:Anticarcinogenic Agents / Q000494:pharmacology*; D000975:Antioxidants / Q000494:pharmacology*; D001205:Ascorbic Acid; D002084:Butylated Hydroxytoluene; D006528:Carcinoma, Hepatocellular / Q000473:pathology / Q000517:prevention & control; D018736:DNA Adducts / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008113:Liver Neoplasms / Q000473:pathology / Q000517:prevention & control; D009152:Mutagenicity Tests; D009153:Mutagens / Q000633:toxicity; D009154:Mutation / Q000187:drug effects*; D012503:Saponins / Q000494:pharmacology*; D013025:Glycine max / Q000737:chemistry*; D016896:Treatment Outcome; D014407:Tumor Cells, Cultured; D024502:alpha-Tocopherol
D016588:Anticarcinogenic Agents; D000975:Antioxidants; D018736:DNA Adducts; D009153:Mutagens; D012503:Saponins; D002084:Butylated Hydroxytoluene; D016604:Aflatoxin B1; D024502:alpha-Tocopherol; D001205:Ascorbic Acid